• LAST PRICE
    13.7500
  • TODAY'S CHANGE (%)
    Trending Up0.0200 (0.1457%)
  • Bid / Lots
    13.1900/ 1
  • Ask / Lots
    14.6800/ 1
  • Open / Previous Close
    13.6000 / 13.7300
  • Day Range
    Low 12.8700
    High 14.8500
  • 52 Week Range
    Low 9.3900
    High 29.5100
  • Volume
    2,177
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 13.73
TimeVolumeJANX
09:32 ET25013.6
09:41 ET10013.73
09:43 ET10013.73
09:48 ET10014.85
09:52 ET10014.39
09:57 ET10014.425
10:12 ET63013.75
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesJANX
Janux Therapeutics Inc
532.5M
-10.4x
---
United StatesSTOK
Stoke Therapeutics Inc
495.1M
-5.1x
---
United StatesKNTE
Kinnate Biopharma Inc
523.0M
-5.1x
---
United StatesPMVP
PMV Pharmaceuticals Inc
520.1M
-8.1x
---
United StatesRPTX
Repare Therapeutics Inc
491.9M
-4.0x
---
United StatesCMPS
Compass Pathways PLC
489.4M
-5.6x
---
As of 2022-10-05

Company Information

Janux Therapeutics, Inc. is a biopharmaceutical company that is engaged in developing a pipeline of immunotherapies by applying its technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to treat patients suffering from cancer. The Company's initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. It is developing a pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr and TROP2-TRACTr. Its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. Its TRACIr program targets PD-L1xCD28.

Contact Information

Headquarters
10955 Vista Sorrento Parkway, Suite 200SAN DIEGO, CA, United States 92130
Phone
858-751-4493
Fax
302-655-5049

Executives

Chairman of the Board
Jay Lichter
President, Chief Executive Officer, Founder, Director
David Campbell
Acting Chief Financial Officer
Tighe Reardon
Chief Scientific Officer
Shahram Salek-Ardakani
Chief Business Officer
Andy Meyer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$532.5M
Revenue (TTM)
$6.7M
Shares Outstanding
41.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.32
Book Value
$8.80
P/E Ratio
-10.4x
Price/Sales (TTM)
79.1
Price/Cash Flow (TTM)
---
Operating Margin
-820.27%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.